# Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer

> **NCT06048705** · PHASE1 · TERMINATED · sponsor: **Adaptimmune** · enrollment: 7 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** GSK3901961
- **DRUG:** Cyclophosphamide
- **DRUG:** Fludarabine

## Key facts

- **NCT ID:** NCT06048705
- **Lead sponsor:** Adaptimmune
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-09
- **Primary completion:** 2023-06-08
- **Final completion:** 2023-06-08
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** The study was terminated due to a change in GSK's R\&D priorities.
- **Last updated:** 2024-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06048705

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06048705, "Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06048705. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*